SG11201900125PA - Novel processes for preparation of soluble guanylate cyclase stimulators - Google Patents
Novel processes for preparation of soluble guanylate cyclase stimulatorsInfo
- Publication number
- SG11201900125PA SG11201900125PA SG11201900125PA SG11201900125PA SG11201900125PA SG 11201900125P A SG11201900125P A SG 11201900125PA SG 11201900125P A SG11201900125P A SG 11201900125PA SG 11201900125P A SG11201900125P A SG 11201900125PA SG 11201900125P A SG11201900125P A SG 11201900125PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- compound
- preparation
- english
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359430P | 2016-07-07 | 2016-07-07 | |
| PCT/US2017/040817 WO2018009602A2 (fr) | 2016-07-07 | 2017-07-06 | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900125PA true SG11201900125PA (en) | 2019-02-27 |
Family
ID=59351140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900125PA SG11201900125PA (en) | 2016-07-07 | 2017-07-06 | Novel processes for preparation of soluble guanylate cyclase stimulators |
| SG10202100168XA SG10202100168XA (en) | 2016-07-07 | 2017-07-06 | Novel processes for preparation of soluble guanylate cyclase stimulators |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100168XA SG10202100168XA (en) | 2016-07-07 | 2017-07-06 | Novel processes for preparation of soluble guanylate cyclase stimulators |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11834444B2 (fr) |
| EP (1) | EP3481821B1 (fr) |
| JP (1) | JP7054395B2 (fr) |
| KR (1) | KR102513357B1 (fr) |
| CN (1) | CN109563086B (fr) |
| AU (1) | AU2017292811B2 (fr) |
| BR (1) | BR112019000292A2 (fr) |
| CA (1) | CA3029376A1 (fr) |
| CL (1) | CL2019000017A1 (fr) |
| EA (1) | EA201990236A1 (fr) |
| ES (1) | ES2962829T3 (fr) |
| IL (1) | IL263994B (fr) |
| JO (1) | JOP20180126A1 (fr) |
| MA (1) | MA45593A (fr) |
| MX (1) | MX2019000138A (fr) |
| SG (2) | SG11201900125PA (fr) |
| WO (1) | WO2018009602A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3481818B1 (fr) * | 2016-07-07 | 2023-09-06 | Cyclerion Therapeutics, Inc. | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
| WO2019161534A1 (fr) * | 2018-02-22 | 2019-08-29 | Ironwood Pharmaceuticals, Inc. | Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble |
| BR112020013985A2 (pt) | 2018-01-10 | 2020-12-01 | Cyclerion Therapeutics, Inc. | novos processos e intermediários para a preparação de estimulantes de guanilato ciclase solúvel |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101955439A (zh) * | 2009-07-14 | 2011-01-26 | 华东理工大学 | 一种α-取代-2-氨基乙酰胺的拆分方法 |
| AR088020A1 (es) | 2010-06-30 | 2014-05-07 | Ironwood Pharmaceuticals Inc | Compuestos heterociclicos como estimuladores de sgc |
| CN103403001B (zh) * | 2011-01-13 | 2016-08-17 | 诺瓦提斯公司 | 杂环衍生物及其在神经性疾病治疗中的应用 |
| WO2013101830A1 (fr) | 2011-12-27 | 2013-07-04 | Ironwood Pharmaceuticals, Inc. | Pyrazoles 2-benzyle, 3-(pyrimidin-2-yle)-substitués utiles comme stimulateurs de scg |
| EP2970243B1 (fr) | 2013-03-15 | 2019-11-27 | Cyclerion Therapeutics, Inc. | Stimulateurs de sgc |
| CN107406422B (zh) * | 2014-09-17 | 2022-02-01 | 赛科理音医疗有限公司 | 作为sGC刺激剂的吡唑衍生物 |
| KR20180086497A (ko) * | 2015-11-30 | 2018-07-31 | 아이언우드 파마슈티컬스, 인코포레이티드 | sGC 자극제를 포함하는 고체 분산물 |
| EP3481818B1 (fr) | 2016-07-07 | 2023-09-06 | Cyclerion Therapeutics, Inc. | Nouveaux procédés de préparation de stimulateurs de la guanylate cyclase soluble |
| WO2018009609A1 (fr) | 2016-07-07 | 2018-01-11 | Ironwood Pharmaceuticals, Inc. | Formes solides d'un stimulateur de la gcs |
-
2017
- 2017-07-06 MX MX2019000138A patent/MX2019000138A/es unknown
- 2017-07-06 SG SG11201900125PA patent/SG11201900125PA/en unknown
- 2017-07-06 JP JP2019500469A patent/JP7054395B2/ja active Active
- 2017-07-06 KR KR1020197003461A patent/KR102513357B1/ko active IP Right Grant
- 2017-07-06 BR BR112019000292-8A patent/BR112019000292A2/pt active Search and Examination
- 2017-07-06 AU AU2017292811A patent/AU2017292811B2/en active Active
- 2017-07-06 WO PCT/US2017/040817 patent/WO2018009602A2/fr unknown
- 2017-07-06 EP EP17740238.5A patent/EP3481821B1/fr active Active
- 2017-07-06 US US16/315,221 patent/US11834444B2/en active Active
- 2017-07-06 CA CA3029376A patent/CA3029376A1/fr active Pending
- 2017-07-06 SG SG10202100168XA patent/SG10202100168XA/en unknown
- 2017-07-06 CN CN201780048199.7A patent/CN109563086B/zh active Active
- 2017-07-06 ES ES17740238T patent/ES2962829T3/es active Active
- 2017-07-06 MA MA045593A patent/MA45593A/fr unknown
- 2017-07-06 EA EA201990236A patent/EA201990236A1/ru unknown
-
2018
- 2018-12-24 JO JOP/2018/0126A patent/JOP20180126A1/ar unknown
- 2018-12-27 IL IL263994A patent/IL263994B/en unknown
-
2019
- 2019-01-04 CL CL2019000017A patent/CL2019000017A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019000017A1 (es) | 2019-05-03 |
| CA3029376A1 (fr) | 2018-01-11 |
| EP3481821A2 (fr) | 2019-05-15 |
| CN109563086A (zh) | 2019-04-02 |
| KR102513357B1 (ko) | 2023-03-24 |
| KR20190025987A (ko) | 2019-03-12 |
| AU2017292811A1 (en) | 2019-02-07 |
| BR112019000292A2 (pt) | 2019-04-16 |
| SG10202100168XA (en) | 2021-02-25 |
| IL263994A (en) | 2019-01-31 |
| US11834444B2 (en) | 2023-12-05 |
| US20210284632A1 (en) | 2021-09-16 |
| AU2017292811B2 (en) | 2021-10-21 |
| EP3481821B1 (fr) | 2023-09-06 |
| MA45593A (fr) | 2019-05-15 |
| JOP20180126A1 (ar) | 2019-01-30 |
| EP3481821C0 (fr) | 2023-09-06 |
| WO2018009602A3 (fr) | 2018-03-15 |
| EA201990236A1 (ru) | 2019-08-30 |
| WO2018009602A2 (fr) | 2018-01-11 |
| JP7054395B2 (ja) | 2022-04-13 |
| JP2019524712A (ja) | 2019-09-05 |
| MX2019000138A (es) | 2019-06-10 |
| IL263994B (en) | 2021-10-31 |
| ES2962829T3 (es) | 2024-03-21 |
| CN109563086B (zh) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909615YA (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators |